• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Drug Approved For Multiple Severe Food Allergies In FDA First

February 27, 2024 by Deborah Bloomfield

A drug designed to reduce allergic reactions to more than one type of food has been approved by the US Food and Drug Administration (FDA) for the first time, the organization announced on February 16.

Plenty of treatments targeting individual food allergens have been trialed in the past – but this is the first drug to tackle multiple at once to gain FDA approval, reducing the severity of allergies to foods including peanuts, milk, and eggs in just one shot.

Advertisement

Xolair, or omalizumab, is an injectable monoclonal antibody treatment, which contains immune proteins that bind to the molecule immunoglobulin E (IgE), known to trigger allergic reactions. By prohibiting IgE from binding to its receptors, the drug can curtail Type I reactions, reducing the risk of anaphylaxis upon exposure to multiple foods.

However, Xolair – approved for use in certain adults and children 1 year or older – is not intended for the immediate, emergency treatment of allergic reactions. Instead, it is recommended for repeat use to reduce the likelihood of severe reactions occurring and minimize the risks if they do. 

Injections every two to four weeks serve as a preventative measure to enable patients to build tolerance to food allergens. Importantly, people on the drug should continue to avoid foods they’re allergic to.

Xolair was initially approved for the treatment of allergic asthma in 2003, and is also approved for use in people with chronic spontaneous urticaria and chronic rhinosinusitis with nasal polyps.

Advertisement

“This newly approved use for Xolair will provide a treatment option to reduce the risk of harmful allergic reactions among certain patients with IgE-mediated food allergies,” Dr Kelly Stone, associate director of the Division of Pulmonology, Allergy, and Critical Care in the FDA’s Center for Drug Evaluation and Research, said in a statement. 

“While it will not eliminate food allergies or allow patients to consume food allergens freely, its repeated use will help reduce the health impact if accidental exposure occurs.”

The approval comes off the back of a successful clinical trial, which saw 67 percent of subjects with a peanut allergy and at least two other food allergies able to eat a single dose of peanut protein without moderate to severe allergic symptoms. This is compared to just 7 percent in the control group. Similar rates of improvement were observed when assessing people’s reactions to cashews, milk, and eggs.

However, 17 percent of people had no significant change in their peanut protein tolerance. “As a result, continuation of strict allergen avoidance is still necessary, despite treatment with Xolair,” the FDA added.

Advertisement

Side effects included injection site reactions and fever, and the drug’s label cautions against anaphylaxis, malignancy, fever, joint pain, rash, and parasitic (worm) infection.

As a result, the FDA states Xolair should only be started in a healthcare setting and only for those without a history of known severe hypersensitivity to Xolair or any of its components.

Still, for those with food allergies – around 6 percent of people in the US, according to the Centers for Disease Control and Prevention – Xolair could offer a much-needed new treatment option.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Cricket-NZ players reach Dubai after ‘specific, credible threat’ derailed Pakistan tour
  2. Newly Discovered Sea-Floor Crater Could Be Related To Chicxulub The Dinosaur Killer
  3. Skinwalker Ranch – Bastion For The Paranormal Or Hoax?
  4. What Is The White Smoke Coming Out Of A Car Exhaust?

Source Link: Drug Approved For Multiple Severe Food Allergies In FDA First

Filed Under: News

Primary Sidebar

  • Unethical Experiments: When Scientists Really Should Have Stopped What They Were Doing Immediately
  • The First Humans Were Hunted By Leopards And Weren’t The Apex Predators We Thought They Were
  • Earth’s Passage Through The Galaxy Might Be Written In Its Rocks
  • What Is An Einstein Cross – And Why Is The Latest One Such A Unique Find?
  • If We Found Life On Mars, What Would That Mean For The Fermi Paradox And The Great Filter?
  • The Longest Living Mammals Are Giants That Live Up To 200 Years In The Icy Arctic
  • Entirely New Virus Detected In Bat Urine, And It’s Only The 4th Of Its Kind Ever Isolated
  • The First Ever Full Asteroid History: From Its Doomed Discovery To Collecting Its Meteorites
  • World’s Oldest Pachycephalosaur Fossil Pushes Back These Dinosaurs’ Emergence By 15 Million Years
  • The Hole In The Ozone Layer Is Healing And On Track For Full Recovery In The 21st Century, Thanks To Science
  • First Sweet Potato Genome Reveals They’re Hybrids With A Puzzling Past And 6 Sets Of Chromosomes
  • Why Is The Top Of Canada So Sparsely Populated? Meet The “Canadian Shield”
  • Humans Are In The Middle Of “A Great Evolutionary Transition”, New Paper Claims
  • Why Do Some Toilets Have Two Flush Buttons?
  • 130-Year-Old Butter Additive Discovered In Danish Basement Contains Bacteria From The 1890s
  • Prehistoric Humans Made Necklaces From Marine Mollusk Fossils 20,000 Years Ago
  • Zond 5: In 1968 Two Soviet Steppe Tortoises Beat Humans To Orbiting Around The Moon
  • Why Cats Adapted This Defense Mechanism From Snakes
  • Mother Orca Seen Carrying Dead Calf Once Again On Washington Coast
  • A Busy Spider Season Is Brewing: Why This Fall Could See A Boom Of Arachnid Activity
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version